Literature DB >> 18310216

Health supervision for children with neurofibromatosis.

Joseph H Hersh.   

Abstract

Neurofibromatosis 1 is a multisystem disorder that primarily involves the skin and nervous system. Its population prevalence is 1 in 3500. The condition usually is recognized in early childhood, when cutaneous manifestations are apparent. Although neurofibromatosis 1 is associated with marked clinical variability, most affected children do well from the standpoint of their growth and development. Some features of neurofibromatosis 1 are present at birth, and others are age-related abnormalities of tissue proliferation, which necessitate periodic monitoring to address ongoing health and developmental needs and to minimize the risk of serious medical complications. This clinical report provides a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of neurofibromatosis 1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the growth, development, and health of an affected child.

Entities:  

Mesh:

Year:  2008        PMID: 18310216     DOI: 10.1542/peds.2007-3364

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  40 in total

1.  Giant plexiform neurofibroma with hemorrhage in cranio-maxillofacial region as depicted on CT and MRI.

Authors:  Y Feng; Zhi-Gang Yang; T Chen; Q Wang; W Deng
Journal:  Eur J Med Res       Date:  2010-02-26       Impact factor: 2.175

2.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

Review 3.  Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review.

Authors:  Anna Carolina Paiva Costa T Figueiredo; Nikolas Mata-Machado; Matthew McCoyd; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

4.  Hyperactive interneurons impair learning in a neurofibromatosis model.

Authors:  Kevin J Staley; Anne E Anderson
Journal:  Nat Neurosci       Date:  2009-01       Impact factor: 24.884

5.  fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies.

Authors:  P de Blank; K Cole; L Kersun; A Green; J J Wilkes; J Belasco; R Bagatell; L C Bailey; M J Fisher
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

6.  Impact of vision loss among survivors of childhood central nervous system astroglial tumors.

Authors:  Peter M K de Blank; Michael J Fisher; Lu Lu; Wendy M Leisenring; Kirsten K Ness; Charles A Sklar; Marilyn Stovall; Chris Vukadinovich; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Cancer       Date:  2016-01-11       Impact factor: 6.860

Review 7.  Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

8.  Hilar biliary neurofibroma without neurofibromatosis: case report with contrast-enhanced ultrasound findings.

Authors:  Huan-Ling Guo; Li-da Chen; Zhu Wang; Yang Huang; Jin-Ya Liu; Quan-Yuan Shan; Xiao-Yan Xie; Ming-de Lu; Wei Wang
Journal:  J Med Ultrason (2001)       Date:  2016-07-21       Impact factor: 1.314

Review 9.  Cerebrovascular stenosis in neurofibromatosis type 1 and utility of magnetic resonance angiography: our experience and literature review.

Authors:  Felice D'Arco; Alessandra D'Amico; Ferdinando Caranci; Nilde Di Paolo; Daniela Melis; Arturo Brunetti
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

10.  Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network.

Authors:  Deborah A Bilder; Amanda V Bakian; David A Stevenson; Paul S Carbone; Christopher Cunniff; Alyson B Goodman; William M McMahon; Nicole P Fisher; David Viskochil
Journal:  J Autism Dev Disord       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.